NCT01158599

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

An Open-label, Uncontrolled Phase 4 Study to Assess the Safety and Immunogenicity of the Japanese Encephalitis (JE) Vaccine Ixiaro® (IC51) in an Elderly Population

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Valneva Austria GmbH · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

This is an open-label, uncontrolled phase 4 study to assess the safety and immunogenicity of the Japanese encephalitis (JE) vaccine Ixiaro® (IC51) in an elderly population.

Conditions

• Japanese Encephalitis

Interventions

Type	Name	Description
BIOLOGICAL	IXIARO®	IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28

Timeline

• Start date: 2010-06-01
• Primary completion: 2011-06-01
• Completion: 2011-10-01
• First posted: 2010-07-08
• Last updated: 2012-03-23

Locations

5 sites across 2 countries: Austria, Germany